Neurotrope, Inc. (Nasdaq: NTRP) to Ring The Nasdaq Stock Market Opening Bell
March 30 2017 - 9:24AM
What: Neurotrope, Inc.
(Nasdaq:NTRP), a clinical-stage biopharmaceutical company
developing novel therapeutics for neurodegenerative diseases,
including Alzheimer's disease, will visit the Nasdaq MarketSite in
Times Square.
In honor of the occasion, Joshua N. Silverman, Chairman
of the Board of Directors, will ring the Opening
Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Friday, March 31, 2017 – 9:15 a.m. to 9:30
a.m. ET
Neurotrope Media Contact:Jeffrey
Benison212.334.8709 or
516.286.6099jbenison@neurotropebioscience.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies, please visit
our Facebook page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Opening
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to
treat and potentially reverse moderate to severe Alzheimer's
dementia and other neurodegenerative diseases. The Company's
world-class science is a paradigm shifting approach that treats
some of the underlying causes of Alzheimer's disease.
The scientific basis of our treatment is activation of Protein
Kinase C isozymes ε and α by bryostatin-1, a natural product, which
in mouse Alzheimer's disease models was demonstrated to result in
repair of damaged synapses as well as synaptogenesis, the induction
of new neuronal networks, reduction of toxic beta-amyloid
generation, prevention of neuronal death, and enhancement of memory
and learning, thus having the potential to improve cognition and
behavior in Alzheimer's dementia.
Neurotrope is conducting a Phase 2 trial of bryostatin-1 in the
treatment of moderate to severe Alzheimer's dementia, as well as
preclinical studies of bryostatin-1 as a treatment for Fragile X
Syndrome, Niemann-Pick Type C disease and Rett Syndrome, three rare
genetic diseases for which only symptomatic treatments are
currently available. The FDA has granted Orphan Drug Designation to
Neurotrope for bryostatin-1 as a treatment for Fragile X
Syndrome. Bryostatin-1 has undergone testing in over 1,500
people establishing a large safety database.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables clients to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 85
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to approximately 3,800 listed
companies with a market value of $10.1 trillion and nearly 18,000
corporate clients. To learn more, visit: business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2024 to May 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From May 2023 to May 2024